Pieris Pharmaceuticals Vergangene Ertragsentwicklung
Vergangenheit Kriterienprüfungen 0/6
Die Gewinne von Pieris Pharmaceuticals sind jährlich um durchschnittlich 5.2% gestiegen, während die Gewinne der Branche Biotechs jährlich um gewachsen um 19.1% gestiegen sind. Die Umsätze sind jährlich um rückläufig 11.9% gestiegen.
Wichtige Informationen
5.2%
Wachstumsrate der Gewinne
16.4%
EPS-Wachstumsrate
| Biotechs Wachstum der Industrie | 17.0% |
| Wachstumsrate der Einnahmen | -11.9% |
| Eigenkapitalrendite | -98.1% |
| Netto-Marge | -1,180.0% |
| Letzte Ertragsaktualisierung | 30 Sep 2024 |
Jüngste Aktualisierungen vergangener Leistungen
Recent updates
The Market Doesn't Like What It Sees From Pieris Pharmaceuticals, Inc.'s (NASDAQ:PIRS) Revenues Yet As Shares Tumble 30%
Jul 11
Why Investors Shouldn't Be Surprised By Pieris Pharmaceuticals, Inc.'s (NASDAQ:PIRS) 27% Share Price Plunge
Apr 21We Think Pieris Pharmaceuticals (NASDAQ:PIRS) Needs To Drive Business Growth Carefully
Mar 19Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) Not Doing Enough For Some Investors As Its Shares Slump 27%
Dec 18We Think Pieris Pharmaceuticals (NASDAQ:PIRS) Needs To Drive Business Growth Carefully
Aug 18Analysts Just Shaved Their Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) Forecasts Dramatically
May 15Why Investors Shouldn't Be Surprised By Pieris Pharmaceuticals, Inc.'s (NASDAQ:PIRS) 41% Share Price Plunge
Apr 17Can Pieris Pharmaceuticals (NASDAQ:PIRS) Afford To Invest In Growth?
Dec 31Bearish: This Analyst Is Revising Their Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) Revenue and EPS Prognostications
Aug 10Pieris Pharmaceuticals GAAP EPS of -$0.14 misses by $0.03, revenue of $3.7M misses by $6.77M
Aug 04Pieris: Early Stage Developer Of Novel Asset Class
Jan 09We're Not Very Worried About Pieris Pharmaceuticals' (NASDAQ:PIRS) Cash Burn Rate
Dec 15Progress At Pieris Pharmaceuticals
Oct 27Analysts Just Made A Noticeable Upgrade To Their Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) Forecasts
Aug 05We Think Pieris Pharmaceuticals, Inc.'s (NASDAQ:PIRS) CEO Compensation Package Needs To Be Put Under A Microscope
Jun 19Need To Know: Analysts Just Made A Substantial Cut To Their Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) Estimates
May 22Will Pieris Pharmaceuticals (NASDAQ:PIRS) Spend Its Cash Wisely?
May 19Analysts Are Betting On Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) With A Big Upgrade This Week
Apr 01Here's What Pieris Pharmaceuticals, Inc.'s (NASDAQ:PIRS) Shareholder Ownership Structure Looks Like
Mar 08We're Keeping An Eye On Pieris Pharmaceuticals' (NASDAQ:PIRS) Cash Burn Rate
Feb 01How Much Did Pieris Pharmaceuticals'(NASDAQ:PIRS) Shareholders Earn From Share Price Movements Over The Last Three Years?
Dec 28
How Does Pieris Pharmaceuticals' (NASDAQ:PIRS) CEO Salary Compare to Peers?
Dec 02Aufschlüsselung der Einnahmen und Ausgaben
Wie Pieris Pharmaceuticals Geld verdient und ausgibt. Basierend auf den neuesten gemeldeten Einnahmen der letzten zwölf Monate.
Gewinn- und Umsatzhistorie
| Datum | Einnahmen | Umsatz | Allgemeine und Verwaltungskosten | F&E-Ausgaben |
|---|---|---|---|---|
| 30 Sep 24 | 1 | -16 | 13 | -36 |
| 30 Jun 24 | 21 | -24 | 17 | 0 |
| 31 Mar 24 | 41 | -16 | 17 | 0 |
| 31 Dec 23 | 43 | -25 | 17 | 0 |
| 30 Sep 23 | 47 | -28 | 19 | 0 |
| 30 Jun 23 | 33 | -27 | 16 | 0 |
| 31 Mar 23 | 17 | -41 | 16 | 0 |
| 31 Dec 22 | 26 | -33 | 16 | 0 |
| 30 Sep 22 | 28 | -35 | 16 | 0 |
| 30 Jun 22 | 27 | -42 | 17 | 0 |
| 31 Mar 22 | 27 | -47 | 17 | 0 |
| 31 Dec 21 | 31 | -46 | 17 | 0 |
| 30 Sep 21 | 25 | -51 | 16 | 0 |
| 30 Jun 21 | 24 | -48 | 16 | 0 |
| 31 Mar 21 | 32 | -38 | 16 | 0 |
| 31 Dec 20 | 29 | -37 | 17 | 0 |
| 30 Sep 20 | 45 | -26 | 18 | 0 |
| 30 Jun 20 | 57 | -15 | 18 | 0 |
| 31 Mar 20 | 51 | -22 | 18 | 0 |
| 31 Dec 19 | 46 | -28 | 18 | 0 |
| 30 Sep 19 | 34 | -36 | 19 | 13 |
| 30 Jun 19 | 27 | -40 | 18 | 24 |
| 31 Mar 19 | 33 | -28 | 19 | 34 |
| 31 Dec 18 | 29 | -27 | 18 | 41 |
| 30 Sep 18 | 42 | -8 | 21 | 33 |
| 30 Jun 18 | 38 | -8 | 19 | 28 |
| 31 Mar 18 | 28 | -18 | 18 | 24 |
| 31 Dec 17 | 25 | -18 | 18 | 22 |
| 30 Sep 17 | 10 | -32 | 14 | 23 |
| 30 Jun 17 | 7 | -31 | 13 | 22 |
| 31 Mar 17 | 6 | -27 | 11 | 21 |
| 31 Dec 16 | 6 | -23 | 9 | 19 |
| 30 Sep 16 | 5 | -19 | 9 | 15 |
| 30 Jun 16 | 5 | -17 | 9 | 13 |
| 31 Mar 16 | 4 | -15 | 8 | 10 |
| 31 Dec 15 | 3 | -14 | 9 | 8 |
| 30 Sep 15 | 4 | -15 | 10 | 7 |
| 30 Jun 15 | 4 | -13 | 8 | 6 |
| 31 Mar 15 | 4 | -13 | 9 | 6 |
| 31 Dec 14 | 5 | -10 | 7 | 5 |
| 30 Sep 14 | 6 | -5 | 5 | 5 |
| 31 Dec 13 | 12 | 0 | 3 | 9 |
Qualität der Erträge: PIRS ist derzeit unrentabel.
Wachsende Gewinnspanne: PIRS ist derzeit unrentabel.
Analyse von freiem Cashflow und Gewinn
Analyse des Gewinnwachstums in der Vergangenheit
Ergebnisentwicklung: PIRS ist unrentabel, hat aber in den letzten 5 Jahren die Verluste mit einer Rate von 5.2% pro Jahr reduziert.
Beschleunigtes Wachstum: Das Gewinnwachstum des letzten Jahres kann nicht mit dem 5-Jahres-Durchschnitt von PIRS verglichen werden, da das Unternehmen derzeit nicht profitabel ist.
Erträge im Vergleich zur Industrie: PIRS ist unrentabel, was einen Vergleich des Gewinnwachstums des letzten Jahres mit der Branche Biotechs (16.6%) erschwert.
Eigenkapitalrendite
Hohe Eigenkapitalrendite: PIRS hat eine negative Eigenkapitalrendite (-98.06%), da es derzeit unrentabel ist.